Effect of the antimicrobial stewardship protocol on the results of treatment of ICU patients with respiratory infections in a multidisciplinary hospital. Article
ISSN (print) 1726-9806     ISSN (online) 1818-474X
#2020-2
PDF_2020-02_96-103 (Russian)
HTML_2020-02_96-103 (Russian)

Keywords

respiratory infection
antimicrobial resistance
antimicrobial stewardship

How to Cite

1.
Zamyatin M.N., Vekshina O.A., Gusarov V.G., Kuzminov S.U., Bardin I.V., Knyazeva P.A. Effect of the antimicrobial stewardship protocol on the results of treatment of ICU patients with respiratory infections in a multidisciplinary hospital. Article. Annals of Critical Care. 2020;(2):96-103. doi:10.21320/1818-474X-2020-2-96-103

Statistic

Abstract Views: 81
PDF_2020-02_96-103 (Russian) Downloads: 26
HTML_2020-02_96-103 (Russian) Downloads: 14
Statistic from 01.07.2024

Language

English Русский

Social Networks

Abstract

The purpose of the study was to evaluate the effectiveness of implementation in real practice of multidisciplinary hospital ICU a local Protocol for the treatment of respiratory infections. Materials and methods. The retrospective interventional study with historical control was performed in a regional clinical hospital with 940 beds. The Protocol was based on the results of local bacteriological data and included indications for start therapy, algorithm for selecting and canceling the antibiotic treatment. We included in analysis data from all patients with pneumonia and purulent tracheobronchitis who were treated in ICU for previous andnext year after the implementation of the Protocol (pre- and intervention period). In accordance with the diagnostic criteria, a group of 146 patients was formed out of 1090 patients who were treated in ICU in preintervention period and to compare with 174 patients group in the interventional period out of 1465 ICU patients. Results. The implementation of the Protocol helped to reduce the average duration of the AMT course from 13.7 to 10.4 days, p < 0.01, the frequency of recurrence of pulmonary infection (22.6 % and 12.6 %, p = 0.028), the duration of artificial ventilation (p < 0.01) and treatment in ICU (for 3 days, p = 0.025). Overall mortality in the groups decreased insignificantly (p = 0.06). Conclusion. Protocol for respiratory infections treatment is an effective tool for control of antimicrobial therapy. The implementation of the Protocol helps physician to timely and reasonably prescribe those antibiotics to the patient that will ensure an early start of effective therapy, and then also reasonably change the scheme or stop therapy. As a result, treatment results are improved, the probability of progression or recurrence of infection is reduced, the need of ventilatory support is reduced, as well as the duration of respiratory support and stay of patients in the ICU.
PDF_2020-02_96-103 (Russian)
HTML_2020-02_96-103 (Russian)

References

  1. Нозокомиальная пневмония у взрослых: Российские национальные рекомендации. Под ред. акад. РАН Б.Р. Гельфанда; отв. ред. к. м. н., доцент Д.Н. Проценко, к. м. н., доцент Б.З. Белоцерковский. 2-е изд., перераб. и доп. М.: Медицинское информационное агентство, 2016. [Nosocomial pneumonia in adults: Russian National guidelines. Gelfand B.R. Moscow: MIA, 2016. (In Russ)]
  2. Яковлев С.В., Суворова М.П., Белобородов В.Б. и др. Распространенность и клиническое значение нозокомиальных инфекций в лечебных учреждениях России: исследование ЭРГИНИ. Антибиотики и химиотерапия. 2016; 61(5–6): 32–42. [Yakovlev S.V., Suvorova M.P., Beloborodov V.B., et al. Multicenter Study of the Prevalence and Clinical value of Hospital-Acquired Infections of Emergency Hospitals in Russia: ERGINI Study Team. Antibiot Khimioter. 2016; 61(5–6): 32–42. (In Russ)]
  3. Chastre J., Fagon J.Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002; 165(7): 867–903. Review.
  4. Welte T., Torres A., Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012; 67(1): 71–79.
  5. Torres A., Zhong N., Pachl J., et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2017; pii: S1473-3099(17)30747-8.
  6. Kollef M.H., Nováček M., Kivistik Ü., et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019; 19(12): 1299–1311. DOI: 10.1016/S1473-3099(19)30403-7. Epub 2019 Sep 25.
  7. Ferrer R., Martin-Loeches I., Phillips G., et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014; 42(8): 1749–1755.
  8. Стратегия и тактика применения антимикробных средств в лечебных учреждениях России: Российские национальные рекомендации. Под ред. Савельева В.С., Гельфанда Б.В., Яковлева С.В. М.: Компания Боргес, 2012. [Antimicrobial Stewardship Strategy in Russian Hospital: Russian National Guidelines. Savelev V.S., Gelfand B.V., Yakovlev S.V. — Moscow: Company Borges, 2012. (In Russ)]
  9. Программа СКАТ (Стратегия контроля антимикробной терапии) при оказании стационарной медицинской помощи: Российские клинические рекомендации. Под ред. Яковлева С.В., Брико Н.И., Сидоренко С.В., Проценко Д.Н. М.: Перо, 2018. [Antimicrobial Stewardship Strategy (AMS strategy): The Clinical Guidelines. Yakovlev S.V., Briko N.I., Sidorenko S.V., Protsenko D.N. Moscow, 2018. (In Russ)]
  10. Левит А.Л., Сидоренко С.В., Яковлев В.П. и др. Анализ адекватности стартовых эмпирических режимов антибактериальной терапии при тяжелых нозокомиальных инфекциях (исследование АСЭТ). Клиническая фармакология и терапия. 2006: 2; 21–14. [Levit A.L., Sidorenko S.V., Yakovlev V.P., et al. Adequacy and efficacy of initial empiric antibiotic treatments in severe nosocomial infections in ICU departments: results of multicentre randomised study. Clinical pharmacology and therapy. 2006: 2; 21–14. (In Russ)]
  11. Arnold H.M., Micek S.T., Skrupky L.P., Kollef M.H. Antibiotic stewardship in the intensive care unit. Semin Respir Crit Care Med. 2011; 32: 215–227.
  12. Leuthner K.D., Doern G.V. Antimicrobial stewardship programs. J Clin Microbiol. 2013; 51: 3916–3920.
  13. Гусаров В.Г. Замятин М.Н., Теплых Б.А. Антибиотикорезистентность: пути решения проблемы в многопрофильном стационаре. Вестник Национального медико-хирургического центра им. Н.И. Пирогова. 2014; 9(3): 108–113. [Gusarov V.G., Zamjatin M.N., Teplyh B.A. Antibiotic Resistance: Possible Solutions In A Multidisciplinary Hospital. Bulletin of Pirogov National medical and surgical center. 2014; 9(3): 108–113. (In Russ)]
  14. CDC. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https://www.cdc.gov/antibiotic-use/core-elements/hospital.html
  15. Руднов В.А., Колотова Г.Б., Багин В.А. и др. Управление антимикробной терапией в службе реанимации и интенсивной терапии КМАХ. 2018; 20(2): 132–140. DOI: 10.36488/cmac.2018.2.132-140. [Rudnov V.A., Kolotova G.A., Bagin V.A., et al. The role of antimicrobial therapy stewardship in intensive care service. J Clinical microbiology and antimicrobial chemotherapy. 2018; 2: 132–140. (In Russ)]
  16. Pugh R., Grant C., Cooke R.P., et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev. 2015; 24(8): CD007577.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.